At ASCO 2017, the steadily increasing competitive intensity between Lonsurf (TAS-102, Taiho) and Stivarga (regorafenib, Bayer) will be on display . In addition, the I/O agents are reading out both as monotherapy in specific (dMMR/MSI-H) patient segments, as well as in combinations with other cytotoxic and targeted agents in broader patient […]